Welcome to the Platinum Study Program

You play a vital role in the Platinum Program. By staying current with patient recruitment efforts, your participation helps advance important research in the field of Alzheimer’s Disease, helping support patients and caregivers through this serious healthcare challenge.

This portal is meant to be a convenient resource for study teams and investigators to stay informed on recruitment events and milestones in the Platinum Study for Mild to Moderate Alzheimer’s Disease. If you have any questions, please contact your Clinical Study Team Leader listed below.

Protocol ABC-001-AB-ALZ-2001

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group,
Multi‑Center, Biomarker, Safety, and Pharmacokinetic Study of Medication A (ABC‑001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer’s Disease

Protocol highlights:

Length of treatment period: 2 years
Length of study participation: 120 weeks
Number of clinic visits: 28
Total Enrollment Goal: 125
Total number of sites: 25
FSFV: December 2014
LSFV: March 2016

---